Galenica Sustainability and Business Performance
About Galenica
Market environment
Business performance
Governance
Sustainability
Outlook
Swiss pharmaceutical market: Galenica as key driver of generic substitution in the
Swiss pharmacy channel
Drugs reimbursable by health insurance
in Swiss pharmacy channel 2021
(by packs, total 78.8 million)
08/08/22
18.9%
21.4%
6.1%
27.6%
26.0%
■ Patent protected products
4.8 million, +4.9%
Products with expired patent
protection without generics
20.5 million, +1.1%
Generics
21.8 million, +5.1%
Originals1
14.9 million, -1.0%
Others²
16.9 million, +5.3%
Market with generics potential
57.2 million, +2.0%
Substitution rate market³
59.4%
Substitution rate Pharmacies
Galenica Group4
73.5%
Galenica Group: increase of generic
substitution rate in 20214
+1.5pp
Market with generics
36.7 million, +2.5%
Source: IQVIA Switzerland -Swiss pharmaceutical market 2021, Market Segmentation,
reimbursable products (FOPH) in the pharmacy channel. Monthly calculation basis,
delineated market division, data as of December 2021
1) Products with expired patent protection and at least one generic
2)
1. Natural substance (e.g. vitamins, minerals, herbal ingredients)
2. Vaccines
3. Biosimilars
4. Reference products
3) Generics 21.8 million / market with generics 36.7 million = 59.4%
32
4) Source: Galenica Group
GALENICAView entire presentation